These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 832652)

  • 41. Use of plasma levels in evaluation of procainamide dosage.
    Shaw TR; Kumana CR; Royds RB; Padgham CM; Hamer J
    Br Heart J; 1974 Mar; 36(3):265-70. PubMed ID: 4132893
    [No Abstract]   [Full Text] [Related]  

  • 42. Antiarrhythmic drug therapy in survivors of prehospital cardiac arrest: comparison of effects on chronic ventricular arrhythmias and recurrent cardiac arrest.
    Myerburg RJ; Conde C; Sheps DS; Appel RA; Kiem I; Sung RJ; Castellanos A
    Circulation; 1979 May; 59(5):855-63. PubMed ID: 428096
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Plasma concentration of procainamide and prevalence of exertional arrhythmias.
    Gey GO; Levy RH; Fisher L; Pettet G; Bruce RA
    Ann Intern Med; 1974 Jun; 80(6):718-22. PubMed ID: 4832159
    [No Abstract]   [Full Text] [Related]  

  • 44. Conventional and sustained-release procainamide: update on pharmacology and clinical use.
    Anderson JL
    Clin Ther; 1985; 7(5):618-40. PubMed ID: 3902240
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Practolol in treatment of cardiac arrhythmias. I].
    Rymaszewski Z; Poplawska W; Preibisz J
    Kardiol Pol; 1974; 17(1):39-44. PubMed ID: 4820405
    [No Abstract]   [Full Text] [Related]  

  • 46. Haemodynamic effects of procainamide and phenytoin at apparent therapeutic plasma levels.
    Karlsson E; Sonnhag C
    Eur J Clin Pharmacol; 1976 Sep; 10(5):305-10. PubMed ID: 976303
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Comparative bioequivalence and efficacy of two sustained-release procainamide formulations in patients with cardiac arrhythmias.
    Hilleman DE; Patterson AJ; Mohiuddin SM; Ortmeier BG; Destache CJ
    Drug Intell Clin Pharm; 1988; 22(7-8):554-8. PubMed ID: 2458219
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Proceedings: Clinical pharmacology of anti-arrhythmia agents].
    Rahn KH
    Med Klin; 1975 Jun; 70(23):994. PubMed ID: 54865
    [No Abstract]   [Full Text] [Related]  

  • 49. The effects of practolol on the dysrhythmias complicating acute ischemic heart disease.
    Allen JD; Pantridge JF; Shanks RG
    Am J Med; 1975 Feb; 58(2):199-208. PubMed ID: 1115067
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Pharmacodynamics of intravenous procainamide as used during acute electropharmacologic testing.
    Morady F; Kou WH; Schmaltz S; Annesley T; De Buitleir M; Nelson SD; Kushner JA
    Am J Cardiol; 1988 Jan; 61(1):93-8. PubMed ID: 3337024
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The use of practolol in supraventricular arrhythmias associated with acute illnesses.
    Pribble AH; Conn RD
    Am J Cardiol; 1975 May; 35(5):645-50. PubMed ID: 1124718
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Comparison of procainamide and mexiletine in prevention of ventricular arrhythmias after acute myocardial infarction.
    Campbell RW; Dolder MA; Prescott LF; Talbot RG; Murray A; Julian DG
    Lancet; 1975 Jun; 1(7919):1257-60. PubMed ID: 48894
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Maintenance therapy with a new retard tablet preparation of procainamide.
    Hansteen V; Landmark KH; Fremstad D; Dahl SG; Jacobsen S; Marthinsen AA; Waaler T; Frislid K; Lunde PK
    Am Heart J; 1976 Jul; 92(1):47-56. PubMed ID: 785987
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Practolol in the treatment of cardiac arrhythmias. II].
    Poplawska W; Rymaszewski Z
    Kardiol Pol; 1974; 17(1):45-51. PubMed ID: 4820406
    [No Abstract]   [Full Text] [Related]  

  • 55. Antiarrhythmic efficacy of N-acetylprocainamide in patients with premature ventricular contractions.
    Lee WK; Strong JM; Kehoe RF; Dutcher JS; Atkinson AJ
    Clin Pharmacol Ther; 1976 May; 19(5 Pt 1):508-14. PubMed ID: 776488
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Safety and efficacy of procainamide infusions.
    Lima JJ; Goldfarb AL; Conti DR; Golden LH; Bascomb BL; Benedetti GM; Jusko WJ
    Am J Cardiol; 1979 Jan; 43(1):98-105. PubMed ID: 758776
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Comparative evaluation of procainamide and its main metabolite, N-acetylprocainamide, in the acute treatment of ventricular arrhythmias [proceedings].
    Karlsson E; Sonnhag C
    Br J Clin Pharmacol; 1977 Oct; 4(5):632P. PubMed ID: 911617
    [No Abstract]   [Full Text] [Related]  

  • 58. Arrhythmia prophylaxis with procaine amide: plasma concentrations in relation to dose.
    Collste P; Karlsson E
    Acta Med Scand; 1973 Nov; 194(5):405-11. PubMed ID: 4757219
    [No Abstract]   [Full Text] [Related]  

  • 59. Treatment of chronic ventricular arrhythmias [proceedings].
    Krone RJ; Kleiger RE; Oliver GC
    Heart Lung; 1977; 6(1):68-78. PubMed ID: 13053
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The assessment of an antiarrhythmic agent, sustained-release procainamide, with the aid of Holter monitoring.
    Bauer GE; Mitchell AS; Bates F; Hellestrand K
    Med J Aust; 1977 Nov; 2(22):733-5. PubMed ID: 347229
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.